Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Entera Bio Ltd.NASDAQ: ENTX
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$128.87M, compared with -$116.49M a year earlier.
Context
- Retained earnings amounted to 981.6% of total assets at the end of Q1 FY2026, up 442.3 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -10.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (125.37M) USD
- Year-over-year change
- -10.0%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (125.37M) | -10.0% |
| FY2024 | 2024-12-31 | (113.93M) | -9.1% |
| FY2023 | 2023-12-31 | (104.39M) | -9.3% |
| FY2022 | 2022-12-31 | (95.5M) | -15.9% |
| FY2021 | 2021-12-31 | (82.43M) | — |
Retained Earnings vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 retained earnings of -$128.87M is the highest of the 10 companies compared; the peer median is -$467.2M.
- Its year-over-year change of -10.6% is the 6th highest of 10, against a peer median of -5.0%.
- Retained earnings amounts to 981.6% of total assets for ENTX, versus a peer median of 776.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$128.87M | -10.6% | — | 981.6% | |
| Mar 2026 | -$148.72M | -26.3% | — | 500.7% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$254.12M | -72.6% | — | 380.5% |
| Apr 2026 | -$256.76M | -4.1% | — | 1727.3% | |
| Mar 2026 | -$458.27M | +3.2% | — | 776.5% | |
| Mar 2026 | -$467.2M | -32.0% | — | 349.6% | |
| Mar 2026 | -$482.81M | -17.1% | — | 177.4% | |
| Mar 2026 | -$992.32M | -5.0% | — | 843.7% | |
| Mar 2026 | -$1.83B | -4.9% | — | 3686.1% | |
| Mar 2026 | -$2.14B | +2.9% | — | 1149.6% | |
| Peer median (excluding ENTX) | -$467.2M | -5.0% | — | 776.5% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.